Cantex Pharmaceuticals
PrivateLast Round
Series D
Nov 12, 2014
Total Funding Raised
$30.92M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Cantex Pharmaceuticals operates in Healthcare & Life Sciences and is based in Weston, Florida. Its latest recorded funding round was a Series D round in November 2014.
Cantex Pharmaceuticals is a biotechnology company that develops biopharmaceutical technologies designed to improve the treatment of cancers and other life-threatening disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Cantex Pharmaceuticals Comparables
Compare Cantex Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| GlycoMira Therapeutics | 78% | |
| RAGE Biotech | 77% | |
| Arrowhead Pharmaceuticals | 69% |
For institutional investors. Book with your work email.
Cantex Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Nov 12, 2014 | ||||
| Series C | Apr 11, 2014 | ||||
| Grant | Nov 3, 2010 | ||||
| Series B | Aug 25, 2006 | ||||
| Series A | Aug 12, 2002 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Cantex Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Research Corporation Technologies | Series B, Series C, Series A |
| Domain Associates | Series B, Series C, Series D |
| CHL Medical Partners | Series B, Series C |
| The Aurora Funds | Series B, Series C, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 31% MoM.
- Jun 20, 2026
Monthly visitors grew 31% MoM, reaching 1.9K.
For institutional investors. Book with your work email.
Cantex Pharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Cantex Pharmaceuticals's valuation, stock price, and market status.
Is Cantex Pharmaceuticals a public or private company?
Cantex Pharmaceuticals is a private company.
What is the current stock price of Cantex Pharmaceuticals?
Cantex Pharmaceuticals is a private company, so its shares have no public market price. Caplight tracks Cantex Pharmaceuticals's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Cantex Pharmaceuticals worth (valuation)?
Valuation information for Cantex Pharmaceuticals is not publicly available.
Can I buy Cantex Pharmaceuticals stock?
Cantex Pharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Cantex Pharmaceuticals's last funding round?
Cantex Pharmaceuticals's most recent funding round was Series D on November 12, 2014.
Who are the main investors in Cantex Pharmaceuticals?
Key investors in Cantex Pharmaceuticals include Domain Associates.
Will Cantex Pharmaceuticals IPO soon?
No public IPO plans have been announced for Cantex Pharmaceuticals.
How can I track Cantex Pharmaceuticals secondary market activity?
Caplight tracks bids, offers, and trades in Cantex Pharmaceuticals's shares on secondary markets.